Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FBRX 
Forte Biosciences Inc (FBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: FBRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $52.25
1 Year Target Price $52.25
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.07% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 167.35M USD | Price to earnings Ratio - | 1Y Target Price 52.25 |
Price to earnings Ratio - | 1Y Target Price 52.25 | ||
Volume (30-day avg) 4 | Beta 3.03 | 52 Weeks Range 4.11 - 28.68 | Updated Date 10/29/2025 |
52 Weeks Range 4.11 - 28.68 | Updated Date 10/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.81 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.79% | Return on Equity (TTM) -73.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 60953557 | Price to Sales(TTM) - |
Enterprise Value 60953557 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.87 | Shares Outstanding 12432854 | Shares Floating 10221049 |
Shares Outstanding 12432854 | Shares Floating 10221049 | ||
Percent Insiders 4.97 | Percent Institutions 86.71 |
Upturn AI SWOT
Forte Biosciences Inc
Company Overview
History and Background
Forte Biosciences Inc., founded in 2016, focused on developing novel therapies for inflammatory diseases. It went public via reverse merger. In 2021, their lead drug failed a clinical trial, drastically altering their trajectory.
Core Business Areas
- Drug Development (Historical): Focused on developing therapies for inflammatory skin diseases, particularly atopic dermatitis, including FB-401. This is historical as FB-401 failed clinical trials.
- Reverse Merger Target Identification: Currently the primary activity involves seeking a reverse merger partner, having significantly curtailed drug development operations.
Leadership and Structure
Prior to the 2021 FB-401 failure, the company had a CEO and management team focused on clinical trials. Following the failure and layoffs, the leadership is focused on restructuring and finding a suitable reverse merger candidate.
Top Products and Market Share
Key Offerings
- FB-401 (Historical): A live biotherapeutic designed to treat atopic dermatitis. Phase 2 failure significantly impacted the company. Market share was projected but never materialized. Competitors include large pharmaceutical companies like Sanofi (SNY) with Dupixent and Incyte (INCY) with Opzelura.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, marked by high-risk, high-reward ventures. Clinical trial outcomes heavily influence company valuations.
Positioning
Forte Biosciences' position is currently tenuous due to the clinical trial failure. They are seeking a reverse merger, essentially becoming a shell company for another entity to go public. They have no competitive advantages in its current form.
Total Addressable Market (TAM)
The market for atopic dermatitis treatments is estimated in the billions of dollars annually. However, Forte Biosciences has minimal impact due to their failed lead drug and restructuring.
Upturn SWOT Analysis
Strengths
- Cash reserves (post-restructuring)
- Public company listing
Weaknesses
- Failed lead drug candidate
- Lack of pipeline
- Damaged reputation
- Uncertain future
Opportunities
- Successful reverse merger with a promising biotech company
- Licensing or selling existing assets (if any)
Threats
- Failure to find a suitable reverse merger partner
- Depletion of cash reserves
- Delisting from stock exchange
Competitors and Market Share
Key Competitors
- SNY
- INCY
Competitive Landscape
Forte Biosciences currently has no competitive advantages and is not actively competing in the atopic dermatitis market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was tied to FB-401 clinical trials and investor optimism. This growth has ceased.
Future Projections: Future projections depend entirely on the potential reverse merger. Without a merger, the company's future is bleak.
Recent Initiatives: Recent initiatives include cost-cutting measures and seeking a reverse merger partner.
Summary
Forte Biosciences is in a precarious position following the failure of its lead drug. The company's future hinges on finding a suitable reverse merger partner. Its strengths lie in its cash reserves and public listing, but it faces significant weaknesses due to the failed trial and lack of a pipeline. The company needs to quickly execute a beneficial transaction to create value for shareholders.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and represents a snapshot in time. Investment decisions should be based on thorough due diligence and consultation with a financial advisor. The company's situation is dynamic and could change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Forte Biosciences Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2017-04-13 | CEO, President & Chairman Dr. Paul A. Wagner Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.fortebiorx.com |
Full time employees 17 | Website https://www.fortebiorx.com | ||
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.